News

Support Team

2nd December 2020

Multi-stage AI analysis system to support prostate cancer diagnostic imaging

A presentation by Antony Rix

Antony introduces Lucida’s multi-stage AI analysis system to support prostate cancer diagnostic imaging.
EuSoMII Virtual Annual Meeting, 24 October 2020.

Support Team

2nd December 2020

Multi-stage AI analysis system to support prostate cancer diagnostic imaging 

Lucida Medical Limited (AI) system

An Artificial intelligence (AI) system was developed to support interpretation of pre-biopsy prostate multiparametric MRI (mpMRI), aiming to improve patient selection for biopsy, biopsy target identification, and productivity of segmentation and reporting, in the prostate cancer diagnostic pathway.

2nd December 2020

ReIMAGINE

Lucida Medical is part of the ReIMAGINE consortium which seeks to change forever the way in which prostate cancer is diagnosed, the manner in which it is classified, the method by which risk is communicated, the utility associated with the diagnosis, the benefit that is derived from intervention and reduce the overall costs of care.

The precise risk-stratification that results from an image-based measurable-disease approach will allow us to determine whether progression in prostate cancer is clonally specified or is a transitional phenomenon.  

The risk stratification of prostate cancer that will emerge from ReIMAGINE will permit a departure from today’s one-size-fits-all approach towards an individualised care that matches the very broad risk profile of this ill understood disease.

Our Partners

We collaborate with Cambridge University, we are a partner in the ReIMAGINE prostate imaging trial, are in the process of establishing collaborative partnerships with several UK NHS Trust hospitals to help further develop and validate and test Pi, our AI system for detecting prostate cancer from MRI.